A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma.

Trial Profile

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Entinostat (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms ENGAGE-501
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 19 Mar 2014 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015, as per ClinicalTrials.gov record.
    • 31 Jul 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top